Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer
Portfolio Pulse from Vandana Singh
The European Commission approved Bristol Myers Squibb's Abecma for early treatment of relapsed and refractory multiple myeloma, marking it as the first CAR-T therapy for this condition in the EU. Additionally, the company announced positive results from a trial of Opdivo plus Yervoy for advanced hepatocellular carcinoma, showing significant improvement in overall survival. BMY shares rose 0.29% in premarket trading.
March 21, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Abecma approved in EU for blood cancer treatment and positive trial results for Opdivo plus Yervoy in liver cancer, with shares up 0.29% premarket.
The approval of Abecma in the EU for a new indication and positive trial results for another therapy indicate strong potential for Bristol Myers Squibb's product pipeline and market expansion. These developments are likely to positively influence investor sentiment and the company's stock price in the short term, as evidenced by the premarket trading uptick.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100